Serum follistatin in patients with prostate cancer metastatic to the bone

Clinical and Experimental Metastasis

Volumn 27, Issue 8, 2010, Pages 549-555

  Tumminello, Francesca Maria ^a   Badalamenti, Giuseppe ^a   Fulfaro, Fabio ^a   Incorvaia, Lorena ^a   Crescimanno, Marilena ^a   Flandina, Carla ^a   Sepporta, Maria Vittoria ^a   Leto, Gaetano ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Activin; Bone metastasis; Cancer; Follistatin; Prostate cancer; Transforming growth factor ; Tumor markers

Indexed keywords

FOLLISTATIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY;

ACTIVINS; AGED; BONE NEOPLASMS; FOLLISTATIN; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 78649317242     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-010-9344-x     Document Type: Article

References (54)

1. C Welt Y Sidis H Keutmann A Schneyer 2002 Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium Exp Biol Med 227 724 752 1:CAS:528:DC%2BD38XntlyqsLg%3D
2. YG Chen Q Wang SL Lin, et al. 2006 Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis Exp Biol Med 231 534 544 1:CAS:528:DC%2BD28XktlCqs7g%3D
3. GP Risbridger JF Schmitt DM Robertson 2001 Activins and inhibins in endocrine and other tumors Endocr Rev 22 6 836 858 1:CAS:528: DC%2BD38XltlOgsQ%3D%3D 10.1210/er.22.6.836 11739336 (Pubitemid 34214298)
4. DJ Phillips DM de Kretser 1998 Follistatin: a multifunctional regulatory protein Front Neuroendocrinol 19 4 287 322 1:CAS:528:DyaK1cXntl2iurw%3D 10.1006/frne.1998.0169 9799587 (Pubitemid 28487798)
5. F Aoki I Kojima 2007 Therapeutic potential of follistatin to promote tissue regeneration and prevent tissue fibrosis Endocr J 54 6 849 854 1:CAS:528:DC%2BD1cXjtFagurg%3D 10.1507/endocrj.KR07E-001 17938504 (Pubitemid 351346766)
6. S Werner C Alzheimer 2006 Roles of activin in tissue repair, fibrosis and inflammatory disease Cytokine Growth Factor Rev 17 3 157 171 1:CAS:528:DC%2BD28Xltleltrc%3D 10.1016/j.cytogfr.2006.01.001 16481210 (Pubitemid 43816894)
7. S Inoue S Nomura T Hosoi Y Ouchi H Orimo M Muramatsu 1994 Localization of follistatin, an activin-binding protein, in bone tissues Calcif Tissue Int 55 5 395 397 1:CAS:528:DyaK2MXhvFWhtLg%3D 10.1007/BF00299321 7866921 (Pubitemid 24332749)
8. M Funaba K Ogawa T Murata, et al. 1996 Follistatin and activin in bone: expression and localization during endochondral bone development Endocrinology 137 10 4250 4259 1:CAS:528:DyaK28XlvVSnuro%3D 10.1210/en.137.10.4250 8828484 (Pubitemid 26321873)
9. M Eiken S Swagemakers M Koedeman, et al. 2007 The activin A-follistatin system: potent regulator of human extracellular matrix mineralization Faseb J 21 11 2949 2960 10.1096/fj.07-8080com (Pubitemid 47372761)
10. G Tardif JP Pelletier C Boileau J Martel-Pelletier 2009 The BMP antagonists follistatin and gremlin in normal and early osteoarthritic cartilage: an immunohistochemical study Osteoarthr Cartil 17 2 263 270 1:STN:280:DC%2BD1M7itlaisQ%3D%3D 10.1016/j.joca.2008.06.022 18691909
11. Y Murase N Okahashi T Koseki, et al. 2001 Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A J Cell Physiol 188 2 236 242 1:CAS:528:DC%2BD3MXltVKmtrY%3D 10.1002/jcp.1113 11424090 (Pubitemid 32622914)
12. D Gaddy-Kurten JK Coker E Abe, et al. 2002 Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures Endocrinology 143 1 74 83 1:CAS:528:DC%2BD38XjtVOrsw%3D%3D 10.1210/en.143.1.74 11751595 (Pubitemid 34056405)
13. N Kawabata N Kamiya N Suzuki, et al. 2007 Changes in extracellular activin A: follistatin ratio during differentiation of a mesenchymal progenitor cell line ROB.C26 into osteoblasts and adipocytes Life Sci 81 8 18 1:CAS:528:DC%2BD2sXmsFKqt7k%3D 10.1016/j.lfs.2007.04.011 17512555 (Pubitemid 46891500)
14. K Hayashi T Yamaguchi S Yano, et al. 2009 BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis Biochem Biophys Res Commun 379 2 261 266 1:CAS:528:DC%2BD1MXotlyrsA%3D%3D 10.1016/j.bbrc.2008.12.035 19101512
15. J Borawski B Naumnik M Myśliwiec 2004 Activin A/follistatin system: another link to heparin-induced osteoporosis? Clin Appl Thromb Hemost 10 2 191 192 10.1177/107602960401000213 15094943 (Pubitemid 38490091)
16. GR Mundy 2002 Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 584 593 1:CAS:528:DC%2BD38XlslGqsLo%3D 10.1038/nrc867 12154351 (Pubitemid 37328925)
17. S Kakiuchi Y Daigo T Tsunoda, et al. 2003 Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice Mol Cancer Res 1 7 485 499 1:CAS:528:DC%2BD3sXjvVSltL0%3D 12754296
18. Y Kang PM Siegel W Shu, et al. 2003 A multigenic program mediating breast cancer metastasis to bone Cancer Cell 3 6 537 549 1:CAS:528: DC%2BD3sXltlSmsL4%3D 10.1016/S1535-6108(03)00132-6 12842083 (Pubitemid 36808649)
19. D Razanajaona S Joguet AS Ay, et al. 2007 Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth Cancer Res 67 15 7223 7229 1:CAS:528:DC%2BD2sXosVemtr0%3D 10.1158/0008-5472.CAN-07-0805 17671190 (Pubitemid 47206550)
20. E Bloise HL Couto L Massai, et al. 2009 Differential expression of follistatin and FLRG in human breast proliferative disorders BMC Cancer 9 320 10.1186/1471-2407-9-320 10.1186/1471-2407-9-320 19740438
21. TZ Thomas SM Chapman W Hong, et al. 1998 Inhibins, activins, and follistatins: expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia Prostate 34 1 34 43 1:STN:280: DyaK1c%2FovF2rtQ%3D%3D 10.1002/(SICI)1097-0045(19980101)34:1<34::AID- PROS5>3.0.CO;2-K 9428386 (Pubitemid 28023824)
22. SJ McPherson SL Mellor H Wang, et al. 1999 Expression of activin A and follistatin core proteins by human prostate tumor cell lines Endocrinology 140 11 5303 5309 1:CAS:528:DyaK1MXmvFemtLc%3D 10.1210/en.140.11.5303 10537161
23. Q Wang S Tabatabaei B Planz, et al. 1999 Identification of an activin-follistatin growth modulatory system in the human prostate: secretion and biological activity in primary cultures of prostatic epithelial cells J Urol 161 4 1378 1384 1:CAS:528:DyaK1MXitVersL4%3D 10.1016/S0022-5347(01)61687-2 10081911 (Pubitemid 29426160)
24. GP Risbridger SL Mellor SJ McPherson JF Schmitt 2001 The contribution of inhibins and activins to malignant prostate disease Mol Cell Endocrinol 180 1-2 149 155 1:CAS:528:DC%2BD3MXltVaqsL8%3D 10.1016/S0303-7207(01)00497-X 11451585 (Pubitemid 32645641)
25. P Härkönen S Törn R Kurkela, et al. 2003 Sex hormone metabolism in prostate cancer cells during transition to an androgen-independent state J Clin Endocrinol Metab 88 2 705 712 10.1210/jc.2002-020236 12574203 (Pubitemid 36207812)
26. G Sardana K Jung C Stephan EP Diamandis 2008 Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers J Proteome Res 7 8 3329 3338 1:CAS:528:DC%2BD1cXns1yqsbg%3D 10.1021/pr8003216 18578523
27. G Leto L Incorvaia G Badalamenti, et al. 2006 Activin A circulating levels in patients with bone metastasis from breast or prostate cancer Clin Exp Metastasis 23 2 117 122 1:CAS:528:DC%2BD2sXitFCgtg%3D%3D 10.1007/s10585-006- 9010-5 16841234 (Pubitemid 44440171)
28. JA Hanley BJ McNeil 1982 The meaning and use of the area under a receiver operating characteristic (ROC) curve Radiology 143 29 36 1:STN:280: DyaL387ltFyksQ%3D%3D 7063747
29. JA Hanley BJ McNeil 1983 A method of comparing the areas under receiver operating characteristic curves derived from the same cases Radiology 148 839 884 1:STN:280:DyaL3s3nsVKgtg%3D%3D 6878708
30. RH van Schaik CD Wierikx MA Timmerman, et al. 2000 Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues Br J Cancer 82 112 117 10.1054/bjoc.1999.0886 10638976
31. Q Chen JT Watson SR Marengo, et al. 2006 Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo Cancer Lett 244 2 274 288 1:CAS:528:DC%2BD28XhtVGitrfJ 10.1016/j.canlet.2005.12.027 16500022 (Pubitemid 44485884)
32. MH Vaarala K Porvari A Kyllönen P Vihko 2000 Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression Lab Investig 80 8 1259 1266 1:CAS:528:DC%2BD3cXmtFOgsrk%3D 10.1038/labinvest.3780134 10950117
33. Y Fujii S Kawakami Y Okada, et al. 2000 Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells Am J Physiol Endocrinol Metab 286 6 E927 E931 10.1152/ajpendo.00443.2003
34. H Masuda Y Fukabori K Nakano, et al. 2003 Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer Prostate 54 4 268 274 1:CAS:528:DC%2BD3sXit1Giurs%3D 10.1002/pros.10193 12539225 (Pubitemid 36228163)
35. JT Buijs CA Rentsch G van der Horst, et al. 2007 BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo Am J Pathol 171 3 1047 1057 1:CAS:528:DC%2BD2sXhtV2murfJ 10.2353/ajpath.2007.070168 17724140 (Pubitemid 47441001)
36. L Ye JM Lewis-Russell H Kynaston WG Jiang 2007 Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists J Urol 178 3 1086 1091 1:CAS:528:DC%2BD2sXhtValtrbE 10.1016/j.juro.2007.05.003 17644136 (Pubitemid 47211048)
37. BT Feeley SC Gamradt WK Hsu, et al. 2005 Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer J Bone Miner Res 20 12 2189 2199 1:CAS:528:DC%2BD2MXhtlWntrbL 10.1359/JBMR.050802 16294272 (Pubitemid 41698782)
38. DP Simon S Vadakkadath Meethal AC Wilson, et al. 2009 Activin receptor signaling regulates prostatic epithelial cell adhesion and viability Neoplasia 11 4 365 376 1:CAS:528:DC%2BD1MXjslClu74%3D 19308291
39. AJ Najy KC Day ML Day 2008 ADAM15 supports prostate cancer metastasis by modulating tumor cell-endothelial cell interaction Cancer Res 68 4 1092 1099 1:CAS:528:DC%2BD1cXhvFemtbo%3D 10.1158/0008-5472.CAN-07-2432 18281484 (Pubitemid 351272227)
40. JF Riordan 2001 Angiogenin Methods Enzymol 341 263 267 1:CAS:528:DC%2BD38XjsFKis7o%3D 10.1016/S0076-6879(01)41157-8 11582782 (Pubitemid 32928531)
41. X Gao H Hu J Zhu Z Xu 2007 Identification and characterization of follistatin as a novel angiogenin-binding protein FEBS Lett 581 28 5505 5510 1:CAS:528:DC%2BD2sXhtlagsLnF 10.1016/j.febslet.2007.10.059 17991437 (Pubitemid 350101537)
42. N Yoshioka L Wang K Kishimoto, et al. 2006 A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation Proc Natl Acad Sci USA 103 39 14519 14524 1:CAS:528: DC%2BD28XhtVOgtr3O 10.1073/pnas.0606708103 16971483 (Pubitemid 44484782)
43. T Tsuji Y Sun K Kishimoto, et al. 2005 Angiogenin is translocated to the nucleus of HeLa cells and is involved in ribosomal RNA transcription and cell proliferation Cancer Res 65 4 1352 1360 1:CAS:528:DC%2BD2MXhsFKqtrc%3D 10.1158/0008-5472.CAN-04-2058 15735021 (Pubitemid 40270162)
44. IS Oh GH Kim 2004 Vascular endothelial growth factor upregulates follistatin in human umbilical vein endothelial cells Biotechnol Bioprocess Eng 9 201 206 1:CAS:528:DC%2BD2cXlsleiu70%3D 10.1007/BF02942293
45. M Björklund E Koivunen 2005 Gelatinase-mediated migration and invasion of cancer cells Biochim Biophys Acta 1755 1 37 69 15907591
46. LE Littlepage MD Sternlicht N Rougier, et al. 2010 Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression Cancer Res 70 2224 2234 1:CAS:528:DC%2BC3cXjtFygt74%3D 10.1158/0008-5472.CAN-09-3515 20215503
47. J Krneta J Kroll F Alves, et al. 2008 Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors Cancer Res 66 5686 5695 10.1158/0008-5472.CAN-05-3821
48. H Ogino S Yano S Kakiuchi, et al. 2008 Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice Clin Cancer Res 14 660 667 1:CAS:528:DC%2BD1cXhsFyksbk%3D 10.1158/1078-0432.CCR-07-1221 18245525 (Pubitemid 351231145)
49. CW Seder W Hartojo L Lin, et al. 2009 Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma Neoplasia 11 4 388 396 1:CAS:528:DC%2BD1MXjslClu7w%3D 19308293
50. A Chlenski S Liu LJ Baker, et al. 2004 Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC Cancer Res 64 20 7420 7425 1:CAS:528:DC%2BD2cXosFyntbg%3D 10.1158/0008-5472.CAN-04-2141 15492265 (Pubitemid 39372083)
51. C Stove F Vanrobaeys B Devreese, et al. 2004 Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition Oncogene 23 31 5330 5339 1:CAS:528:DC%2BD2cXlsVOmsLc%3D 10.1038/sj.onc.1207699 15064726 (Pubitemid 39005808)
52. C Planque V Kulasingan CR Smith, et al. 2009 Identification of five candidate lung cancer biomarkers by proteomic analysis of conditioned media of four lung cancer cell lines Mol Cell Proteomics 8 12 2746 2758 1:CAS:528:DC%2BD1MXhsFOgsL7I 10.1074/mcp.M900134-MCP200 19776420
53. YA Goo AY Liu S Ryu, et al. 2009 Identification of secreted glycoproteins of human prostate and bladder stromal cells by comparative quantitative proteomics Prostate 69 1 49 61 1:CAS:528:DC%2BD1MXhsFCns7w%3D 10.1002/pros.20853 18792917
54. HG van der Poel C Hanrahan H Zhong JW Simons 2003 Rapamycin induces Smad activity in prostate cancer cell lines Urol Res 30 380 386 12599018